Clinical trial
Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing…
NCT00042406 · Genmab, Industry · Terminated
Key facts
| NCT number | NCT00042406 |
|---|---|
| Title | Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker |
| Official title | A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active Rheumatoid Arthritis Failing Treatment With Methotrexate and TNF-alpha Blocking Agents |
| Lead sponsor | Genmab, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | HuMax-CD4, Placebo, Humax-CD4 |
| Enrollment | 83 |
| Start date | Mar 4, 2002 |
| Primary completion | Mar 31, 2003 |
| Completion | Mar 31, 2003 |
| First posted | Aug 1, 2002 |
| Last update posted | Apr 28, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: